High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Terwijn, Monique; L.J. van Putten, Wim; Kelder, Angèle; H. J. van der Velden, Vincent; A. Brooimans, Rik; Pabst, Thomas; Maertens, Johan; Boeckx, Nancy; E. de Greef, Georgine; J.M. Valk, Peter; Preijers, Frank; C. Huijgens, Peter; M. Dräger, Angelika; Schanz, Urs; Jongen-Lavrecic, Mojca; J. Biemond, Bart; Passweg, Jakob; van Gelder, Michel; W. Wijermans, Pierre; Graux, Carlos; Bargetzi, Mario; Legdeur, Marie-Cecile; Kuball, Jürgen; de Weerdt, Okke; Chalandon, Yves; Hess, U; F. Verdonck, Leo; W. Gratama, Jan; J.M. Oussoren, Yvonne; J. Scholten, Willemijn; Slomp, Jennita; N. Snel, Alexander; Vekemans, Marie‐Christiane; Löwenberg, Bob; J. Ossenkoppele, Gert; Jan Schuurhuis, Gerrit

doi:10.1200/jco.2012.45.9628

Public

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Published in Journal of Clinical Oncology • Sep 24, 2013

Authors:

Monique Terwijn

Wim L.J. van Putten

Angèle Kelder

Abstract

PURPOSE: Half the patients with acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered responsible for the outgrowth of AML. In many retrospective studies, detection of minimal residual disease (MRD) has been shown to...

Subject

Medicine

Myeloid leukemia

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!